Telomere structure and telomerase in health and disease
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
Telomerase is the enzyme responsible for maintenance of the length of telomeres by addition of guanine-rich repetitive sequences. Telomerase activity is exhibited in gametes and stem and tumor cells. In human somatic cells, proliferation potential is strictly limited and senescence follows approximately 50-70 cell divisions. In most tumor cells, on the contrary, replication potential is unlimited. The key role in this process of the system of the telomere length maintenance with involvement of telomerase is still poorly studied. Undoubtedly, DNA polymerase is not capable of completely copying DNA at the very ends of chromosomes; therefore, approximately 50 nucleotides are lost during each cell cycle, which results in gradual telomere length shortening. Critically short telomeres cause senescence, following crisis and cell death. However, in tumor cells the system of telomere length maintenance is activated. Much work has been done regarding the complex telomere/telomerase as a unique target, highly specific in cancer cells. Telomeres have additional proteins that regulate the binding of telomerase. Telomerase, also associates with a number of proteins forming the sheltering complex having a central role in telomerase activity. This review focuses on the structure and function of the telomere/telomerase complex and its altered behavior leading to disease, mainly cancer. Although telomerase therapeutics are not approved yet for clinical use, we can assume that based on the promising in vitro and in vivo results and successful clinical trials, it can be predicted that telomerase therapeutics will be utilized soon in the combat against malignancies and degenerative diseases. The active search for modulators is justified, because the telomere/telomerase system is an extremely promising target offering possibilities to decrease or increase the viability of the cell for therapeutic purposes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Telomeres shorten during ageing of human fibroblasts
Harley, C. B., Futcher, A. B., & Greider, C. W. (1990) · Nature · doi:10.1038/345458a0 · Cited by 5,750
The DNA Damage Response: Making It Safe to Play with Knives
Ciccia, A., & Elledge, S. J. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.019 · Cited by 4,368 · cited 1×
“The complex ERCC1-XPF is a structure-specific endonuclease involved in nucleotide excision repair (NER) pathway and crosslink repair (54).”
BackgroundIdentification of a specific telomere terminal transferase activity in tetrahymena extracts
Greider, C. W., & Blackburn, E. H. (1985) · Cell · doi:10.1016/0092-8674(85)90170-9 · Cited by 3,400 · cited 3×
“In most mammals, the maintenance of telomeric length is carried out mainly by a specific reverse transcriptase, called telomerase that was initially identified in ciliates (6).”
BackgroundInfluentialShelterin: the protein complex that shapes and safeguards human telomeres
de Lange, T. (2005) · Genes & Development · doi:10.1101/gad.1346005 · Cited by 3,056 · cited 1×
“shelterin exerts its roles on telomere function through the transient recruitment of accessory factors (34) and can be viewed for some aspects of telomere function as an assembly line for them.”
Mammalian Telomeres End in a Large Duplex Loop
Griffith, J. D., Comeau, L., Rosenfield, S., Stansel, R. M., Bianchi, A., Moss, H., & de Lange, T. (1999) · Cell · doi:10.1016/s0092-8674(00)80760-6 · Cited by 2,447
Counter, C. M., Avilion, A. A., LeFeuvre, C. E., Stewart, N. G., Greider, C. W., Harley, C. B., & Bacchetti, S. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05245.x · Cited by 2,096 · cited 1×
“This proliferation is followed by ulterior telomeric erosion, until the cells reach a second stage of mortality (M2) whereas the telomeres are critically short (~3 kb) (68).”
BackgroundTRF2 Protects Human Telomeres from End-to-End Fusions
van Steensel, B., Smogorzewska, A., & de Lange, T. (1998) · Cell · doi:10.1016/s0092-8674(00)80932-0 · Cited by 1,709 · cited 1×
“The overexpression of a dominant negative mutant of TRF2 may cause premature senescence (20), and the activation of the apoptotic cascade mediated by the protein kinase ATM and p53”
BackgroundTelomere reduction in human colorectal carcinoma and with ageing
Hastie, N. D., Dempster, M., Dunlop, M. G., Thompson, A. M., Green, D. K., & Allshire, R. C. (1990) · Nature · doi:10.1038/346866a0 · Cited by 1,650
Morin, G. B. (1989) · Cell · doi:10.1016/0092-8674(89)90035-4 · Cited by 1,495 · cited 1×
“In vertebrates, RNA of telomerase has an extension between 382 and 559 nucleotides (86), and in humans in particular the RNA component has an extension of 451 nucleotides of length and contains a sequence of 11 bp (5-CUAACCCUAAC-3') that encodes for telomeric repeats (87).”
BackgroundHerbig, U., Jobling, W. A., Chen, B. P. C., Chen, D. J., & Sedivy, J. M. (2004) · Molecular Cell · doi:10.1016/s1097-2765(04)00256-4 · Cited by 1,344 · cited 1×
“The ATM and ATR signalling kinases are capable of inducing DNA damage response at telomeres in conditions where shelterin activity is impaired or reduced, for example due to telomerase shortening in senescent cells (23).”
Background
Cited by
Wang, F., Lu, C.-H., & Willner, I. (2014) · Chemical Reviews · doi:10.1021/cr400354z · Cited by 649
Telomeres and Telomere Length: A General Overview
Srinivas, N., Rachakonda, S., & Kumar, R. (2020) · Cancers · doi:10.3390/cancers12030558 · Cited by 304
Huang, D.-S., Wang, Z., He, X.-J., Diplas, B. H., Yang, R., Killela, P. J., Meng, Q., Ye, Z.-Y., Wang, W., Jiang, X.-T., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.03.010 · Cited by 193
“Most tumour cells overcome this limitation by re-activating telomerase; however, the mechanisms of this reactivation process remain unknown [1].”
BackgroundPathophysiology of ocular surface squamous neoplasia
Gichuhi, S., Ohnuma, S.-I., Sagoo, M. S., & Burton, M. J. (2014) · Experimental Eye Research · doi:10.1016/j.exer.2014.10.015 · Cited by 161
Telomeres, Telomerase and Ageing
Saretzki, G. (2018) · Subcellular Biochemistry · doi:10.1007/978-981-13-2835-0_9 · Cited by 93
Telomere shortening and immune activity in war veterans with posttraumatic stress disorder
Jergović, M., Tomičević, M., Vidović, A., Bendelja, K., Savić, A., Vojvoda, V., Rac, D., Lovrić-Čavar, D., Rabatić, S., Jovanovic, T., et al. (2014) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2014.06.010 · Cited by 67
Telomere Length Maintenance, Shortening, and Lengthening
Zhao, Z., Pan, X., Liu, L., & Liu, N. (2014) · Journal of Cellular Physiology · doi:10.1002/jcp.24537 · Cited by 66
“However, telomeres can be lengthened by telomerase which is activated in germ line cells, stem cells, and tumor cells (Gomez et al., 2012).”
BackgroundChoi, J. R., Pingguan-Murphy, B., Wan Abas, W. A. B., Yong, K. W., Poon, C. T., Noor Azmi, M. A., Omar, S. Z., Chua, K. H., Xu, F., & Wan Safwani, W. K. Z. (2015) · PLOS ONE · doi:10.1371/journal.pone.0115034 · Cited by 63
“Telomerase is an enzyme involves in the maintenance of telomere length which regulates the cellular proliferative capacity [72].”
Hinterberger, M., Fischer, P., Huber, K., Krugluger, W., & Zehetmayer, S. (2017) · Journal of Neural Transmission · doi:10.1007/s00702-017-1721-z · Cited by 28
“Telomeres are non-coding repetitive DNA sequences (5’TTAGGG3’) protecting the end caps of chromosomes (Gomez et al. 2012) and enabling proper replication of coding DNA.”
BackgroundTelomeres and telomerase in the clinical management of colorectal cancer
Piñol-Felis, C., Fernández-Marcelo, T., Viñas-Salas, J., & Valls-Bautista, C. (2017) · Clinical and Translational Oncology · doi:10.1007/s12094-016-1559-0 · Cited by 13
Metadata
- Authors
- GOMEZ, D. E., ARMANDO, R. G., FARINA, H. G., MENNA, P. L., CERRUDO, C. S., GHIRINGHELLI, P. D., & ALONSO, D. F.
- Venue
- International Journal of Oncology
- Publisher
- Spandidos Publications
- Published
- 2012-08-29
- Volume
- 41
- Issue
- 5
- Pages
- 1561-1569
- ISSN
- 1019-6439 (ISSN-L)
- 1791-2423
- OpenAlex
- W2048621825
- Cited by
- 145
- References
- 29
- FWCI
- 8.87
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.